Blood Cancer

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DCC-073	Gossypol-acetic acid	>98%,Standard References
DC11631	INCB040093	A novel potent, selective, orally available PI3Kδ inhibitor with IC50 of 31 nM.
DC11716	XL-844	A potent, specific, orally available, ATP‑competitive inhibitor of Chk1 and Chk2 with Ki of 2.2 nM and 0.07 nM, respectively.
DC5027	ABC294640（Opaganib） Featured	ABC294640 is an orally available, aryladamantane compound and selective inhibitor of sphingosine kinase-2 (SK2) with potential antineoplastic activity.
DC4127	ABT-263 (Navitoclax) Featured	ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤ 1 nM, respectively.
DC9660	Acalabrutinib(ACP196) Featured	Acalabrutinib (ACP-196) is a second-generation, selective, irreversible inhibitor of BTK.
DC8760	Acalisib Featured	Acalisib (GS-9820) is a potent and selective inhibitor of PI3Kδ with IC50 value of 12.7 nM.
DC8051	AG-120 (Ivosidenib) Featured	AG-120 is a first-in-class, orally available, selective, potent inhibitor of the mutated IDH1 protein.
DC8374	AG-221(Enasidenib) Featured	AG-221 is an orally available, selective, potent inhibitor of the mutated IDH2 protein.
DC2096	AG490 Featured	AG-490 (Tyrphostin B42) is an inhibitor of EGFR, ErbB2 and JAK2 with IC50 of 0.1 μM, 13.5 μM, and ~10 μM, respectively.
DC10439	Vorasidenib (AG881) Featured	AG-881 is a potent and selective orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1) in the cytoplasm and type 2 (IDH2).
DC9366	AMG 900 Featured	AMG 900 is a potent and highly selective pan-Aurora kinases inhibitor for Aurora A/B/C with IC50 of 5 nM/4 nM /1 nM; >10-fold selective for Aurora kinases than p38α, Tyk2, JNK2, Met and Tie2.
DC6311	Pomalidomide Featured	An inhibitor of LPS-induced TNFαrelease.Pomalidomide is thalidomide derivative that displays inhibition of LPS-induced TNFα release. Shows immunomodulator and anticancer effects.
DC1020	Ponatinib (AP24534) Featured	AP24534 is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively.
DC8275	Apilimod Featured	Apilimod(STA 5326) is a potent IL-12/IL-23 inhibitor, IL-12 production in cultures of IFN-r/LPS–stimulated human PBMCs is strongly inhibited by STA-5326 with an IC50 of 10 nM.
DC8664	APTO-253	APTO-253 is a novel small molecule with potent anti-tumor activity in cancer cells via induction of the gene that expresses the Krüppel-like factor 4 (KLF4) master transcription factor, leading to cell cycle inhibition and programmed cell death.
DC9972	ARQ-092(Miransertib) Featured	ARQ 092 is an oral activie, potent and selective AKT inhibitor with IC50 values: 5.0 nM (AKT1); 4.5 nM (AKT2); 16 nM (AKT3).
DC10975	ARQ-531 Featured	ARQ-531 is a potent, reversible, orally available inhibitor of both wild type and C481S-mutant BTK kinase with IC50 of 0.85 and 0.39 nM,
DC7359	Asp-3026 Featured	ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM.
DC2015	AT-101 (AT101)	AT-101 is a BH3 mimetic known to be a potent inhibitor of antiapoptotic Bcl-2 family members.
DC9676	AT7519 Featured	AT7519 is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM; less potent to CDK3 and little active to CDK7.
DC1025	AT7519 HCL Featured	AT7519 is a novel multi-CDK inhibitor for CDK1/cyclin B, CDK2/Cyclin A, CDK3/Cyclin E, CDK4/Cyclin D1, CDK5/p35 and CDK6/Cyclin D3 with IC50 of 210 nM, 47 nM, 360 nM, 100 nM, 13 nM and 170 nM, respectively.
DC9395	AT7519 (trifluoroacetate)	AT7519 trifluoroacetate is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM; less potent to CDK3 and little active to CDK7.
DC7070	AT9283 Featured	AT9283 is a small molecule a multi-targeted inhibitor with of 4, 1.2, 1.1 and approximate 3 nM for Bcr-Abl(T3151), Jak2 and Jak3, aurora A and B, respectively.
DC7367	AZ-960 Featured	AZ 960 is a novel ATP competitive JAK2 inhibitor with IC50 and Ki of <3 nM and 0.45 nM, 3-fold selectivity of AZ960 for JAK2 over JAK3.
DC7060	AZD1152 Featured	AZD1152 (barasertib), pro-drug of barasertib-hQPA, is a selective Aurora B kinase inhibitor, AZD1152 inhibited the proliferation various types of human leukemia cells with an IC50 ranging from 3 nM to 40 nM.
DC10774	AZD5153 Featured	AZD5153 is a potent bivalent triazolopyridazine based Bromodomain and Extraterminal (BET) Inhibitor.
DC2013	Bafetinib (INNO-406) Featured	Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM and 19 nM, respectively.
DC10376	BAY-1143572	BAY 1143572 is a highly selective, potent and orally available inhibitor of PTEFb/CDK9; inhibits the proliferation of AML cell lines with a median IC50 of 385 nM.
DC11719	BAY-1436032	BAY-1436032 (BAY1436032) is a potent, selective, orally available inhibitor of pan-mutant IDH1 with IC50 of 15 nM for both IDH1 R132H and R132C, respectively.

Blood Cancer

Customized Consultation X

Your information is safe with us. * Required Fields.